Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 183, Issue 9, Pages 1187-1192Publisher
AMER THORACIC SOC
DOI: 10.1164/rccm.201008-1220OC
Keywords
biomarker; chronic obstructive pulmonary disease; PARC/CCL-18; chemokine
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- GlaxoSmithKline through a CIHR
- Division of Lung Diseases of the National Heart, Lung, and Blood Institute [N01-HR-46002]
- GlaxoSmithKline [SCO104960]
- AZ
- Wyeth Pharmaceuticals
- Merck Frosst
- NIH
- Covidien Surgical Staples
- BIPI
- Forest
- ALA
- Emphasys
- Intermune
- Telacris
- Otsuka
- Mannkind
- France Foundation
- PCE/PCME
- Breathe LA
- SLU
- NYU
- SUNY
- Wake Forest
- BI
- Dey Pharmaceuticals
- Pfizer
- Dey
- Forrest
- Aeris
- Medical Research Council [G0901786] Funding Source: researchfish
- MRC [G0901786] Funding Source: UKRI
Ask authors/readers for more resources
Rationale: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. Objectives: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 Was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. Measurements and Main Results: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. Conclusions: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available